{"organizations": [], "uuid": "0bfc7ad9625543c81aec7513290056313e649b47", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.wsj.com", "main_image": "http://si.wsj.net/public/resources/images/BN-JW726_0817ki_G_20150817132539.jpg", "site_section": "http://www.wsj.com/news/business", "section_title": "Business &amp; Finance News - Wall Street Journal", "url": "http://www.wsj.com/articles/kite-pharmas-highflying-price-limits-relief-1439833018", "country": "", "title": "Kite Pharma’s Highflying Price Limits Relief", "performance_score": 0, "site": "wsj.com", "participants_count": 1, "title_full": "Kite Pharma’s Highflying Price Limits Relief - WSJ", "spam_score": 0.0, "site_type": "news", "published": "2015-08-17T21:36:00.000+03:00", "replies_count": 0, "uuid": "0bfc7ad9625543c81aec7513290056313e649b47"}, "author": "Charley Grant", "url": "http://www.wsj.com/articles/kite-pharmas-highflying-price-limits-relief-1439833018", "ord_in_thread": 0, "title": "Kite Pharma’s Highflying Price Limits Relief", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "Kite Pharma shareholders can breathe a little easier after Monday morning’s business update—but shouldn’t misread a little relief for wholesale vindication.\nThat was the message on a conference call to update investors on the status of Kite’s early-stage clinical trial for its experimental cancer treatment. Known as KTE-C19, it is designed to restore the immune system’s ability to recognize and attack tumors.\nArie... To Read the Full Story, Subscribe or Sign In", "external_links": [], "published": "2015-08-17T21:36:00.000+03:00", "crawled": "2015-08-17T21:09:56.618+03:00", "highlightTitle": ""}